ImmuCell Corporation is an animal health company. The Company is engaged in the development, acquisition, manufacture, and sale of products that improve the health and productivity of dairy and beef cattle. It operates in two business segments: Scours and Mastitis. The Scours segment is engaged in manufacturing and selling First Defense, a product used to prevent scours in newborn calves. The Mastitis segment includes products called California Mastitis Test and Re-Tain. Re-Tain, a novel treatment for subclinical mastitis in dairy cows, is in the late stages of development. The First Defense product line provides bovine antibodies that newborn calves need but are unable to produce on their own immediately after birth. Its product line extension, Tri-Shield First Defense, is the first calf-level, passive antibody product providing immediate immunity against each of the three causes of calf scours (E. Coli, coronavirus, and rotavirus).
高成長
同社の収益は過去3年間にわたり着実に増加しており、年平均で42.68%の成長率を示しています。
成長中
同社は成長フェーズにあり、最新の年間収益はUSD 26.49Mに達しています。
割高
同社の最新のPEは22.75で、過去3年間の水準と比較して高値圏にあります。
機関投資家の売り越し
最新の機関投資家の保有株数は1.81M株で、前四半期比で5.77%減少しています。
バンガードが保有
スター投資家バンガードは本銘柄を303.00K株保有しています。
市場活動が低調
同社への投資家の関心は低下しており、20日間の売買回転率は-0.54です。